<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132869">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01982578</url>
  </required_header>
  <id_info>
    <org_study_id>INC-GEN-2013-01</org_study_id>
    <secondary_id>U1111-1150-4063</secondary_id>
    <nct_id>NCT01982578</nct_id>
  </id_info>
  <brief_title>Genistein as a Possible Treatment for Alzheimer's Disease.</brief_title>
  <acronym>GENISTEÍNA_2</acronym>
  <official_title>Effect of Activation of the Receptor PPARg/RXR as a Possible Treatment for Alzheimer's Disease. Role of Genistein.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación para la Investigación del Hospital Clínico de Valencia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Valencia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación para la Investigación del Hospital Clínico de Valencia</source>
  <oversight_info>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Genistein is an isoflavone that has antioxidant and neuroprotective effects on Alzheimer's
      disease (AD).

      A few years ago our group reported that genistein increased PPARg (peroxisome proliferator
      activated receptor gamma) levels. By the way, activation of retinoid X receptor (RXR)-PPARg
      dimer, will make overexpressing apolipoprotein E (apoE), which mediates the degradation of
      amyloid beta (AB). Therefore, we believe that if this phytoestrogen administration increases
      the availability of the transcription factor, it can increase apoE, and also AB degradation.

      The main aim of this study is to determinate the effect of 60 mg BID of genistein
      administration, during 180 days, compared to placebo group, in AD patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Amyloid beta concentration in cerebrospinal fluid (CSF). The primary study endpoint is the change from baseline to the end of the treatment, and the change between the treatment group and the placebo group.</measure>
    <time_frame>Day 0 and day 180 (plus or minus 3 day)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>MMSE. Change from baseline to the end of the treatment, and the change between the treatment group and the placebo group.</measure>
    <time_frame>Day 0, day 45, day 180, (plus or minus 3 days)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog). Change from baseline to the end of the treatment, and the change between the treatment group and the placebo group.</measure>
    <time_frame>Day 0, day 45, day 180, (plus or minus 3 days)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Memory alteration test (M@t). Change from baseline to the end of the treatment, and the change between the treatment group and the placebo group.</measure>
    <time_frame>Day 0, day 45, day 180, (plus or minus 3 days)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Is a memory screening test, capable for discriminating between subjects with subjective memory complaints (SMC) (without objective memory impairment) and patients with amnestic mild cognitive impairment (A-MCI) and with mild Alzheimer's disease (AD) (Archives of Gerontology and Geriatrics. 2010 Mar-Apr;50(2):171-4. doi: 10.1016/j.archger.2009.03.005. Epub 2009 Apr 16)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatric Inventory (NPI). Change from baseline to the end of the treatment, and the change between the treatment group and the placebo group.</measure>
    <time_frame>Day 0, day 45, day 180, (plus or minus 3 days)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel index. Change from baseline to the end of the treatment, and the change between the treatment group and the placebo group.</measure>
    <time_frame>Day 0, day 45, day 180, (plus or minus 3 days)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P-TAU concentration in CSF. Change from baseline to the end of the treatment, and the change between the treatment group and the placebo group.</measure>
    <time_frame>Day 0 and day 180 (plus or minus 3 day)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Product: Genistein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg of genistein BID for 180 days. Intervention: Product: Genistein</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 placebo capsule BID for 180 days. Intervention: Product: Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Genistein</intervention_name>
    <description>Subjects will be randomized 1:1 to receive 180 days of double blind treatment of genistein.</description>
    <arm_group_label>Product: Genistein</arm_group_label>
    <other_name>Fisiogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>180 days of double blind treatment of placebo.</description>
    <arm_group_label>Product: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with mild cognitive impairment (MCI) compatible with prodromal AD.

          -  Mini-Mental State Examinations (MMSE) score between over 24 inclusive.

          -  CSF levels of AB, p-TAU compatible with AD.

          -  18 years or older.

          -  Must have a study partner who is able and willing to comply with all required study
             procedures.

          -  Willing and able to provide informed consent by either the subject or subject's legal
             representative.

        Exclusion Criteria:

          -  Patient who does not meet the inclusion criteria.

          -  Thyroid abnormalities with or without treatment.

          -  Immune abnormalities in blood analyses.

          -  Patient suffers hormone dependent neoplasia.

          -  Take a diet rich on isoflavones.

          -  ApoE genotype ε 4/4.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Viña, MD PhD (hon)</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Valencia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jose Viña, MD PhD (hon)</last_name>
    <phone>0034 963864646</phone>
    <phone_ext>64650</phone_ext>
    <email>jose.vina@uv.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitat de València</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Viña, MD PhD (hon)</last_name>
      <phone>0034 963864646</phone>
      <phone_ext>64650</phone_ext>
      <email>jose.vina@uv.es</email>
    </contact>
    <investigator>
      <last_name>Jose Viña, MD PhD (hon)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Miguel Lainez, M.D.</last_name>
      <phone>963 86 26 00</phone>
      <email>jlaineza@medynet.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 20, 2014</lastchanged_date>
  <firstreceived_date>October 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundación para la Investigación del Hospital Clínico de Valencia</investigator_affiliation>
    <investigator_full_name>Jose Vina</investigator_full_name>
    <investigator_title>Professor M.D. Ph. D. (hon)</investigator_title>
  </responsible_party>
  <keyword>Treatment</keyword>
  <keyword>Genistein</keyword>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Cerebrospinal fluid</keyword>
  <keyword>Amyloid beta</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Genistein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
